Product
palbocilib
1 clinical trial
4 indications
Indication
Breast CancerIndication
Locally Advanced Breast CancerIndication
Breast Cancer Stage IIndication
ER+ Breast CancerClinical trial
A Phase I Open-label Dose Escalation Trial of FWD1802 as Monotherapy and in Combination With Palbociclib in Patients With ER+/HER2- Unresectable Locally Advanced or Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2025-11-01